The genetic instructions for creating all the body's proteins are encoded
within the DNA located in the cell nucleus. When the body needs to
produce essential proteins, it doesn't directly utilize this blueprint.
Instead, it replicates and employs it through messenger ribonucleic acid (mRNA).
This intricate biological system enables the body to sustain its functions
while safeguarding the vital design blueprint (DNA) without harm.

Renhaim Inc. is pioneering technology to treat diseases using the mRNA platform.
The mRNA platform encompasses mRNA synthesis and delivery system techniques,
offering a flexible and rapid approach to modifying therapeutic targets.
Furthermore, it capitalizes on established manufacturing processes and
quality control protocols, facilitating the accelerated development of novel medications.

Renhaim Inc. possesses AI-driven mRNA sequence optimization technology,
a diverse range of mRNA synthesis expertise for various lengths, and mRNA synthesis capabilities
that extend from laboratory scale to GMP (Good Manufacturing Practice) scale.

Lipoplex is a structure formed by the interaction of liposomes and mRNA,
effectively protecting physically and chemically unstable mRNA and
delivering it efficiently into the body.

Renhaim Inc. is advancing the Liposome-based Lipoplex technology and conducting
research to build a diverse portfolio of delivery systems for various types of mRNA.